Understanding how MRSA bacteria resist certain antibiotics
Contribution of altered cell envelope metabolism to resistance to cell envelope-targeting antimicrobials in MRSA
This study is looking at how MRSA, a tough bacteria that can resist antibiotics, changes to avoid being killed by treatments like dalbavancin, and the goal is to find better ways to help patients with MRSA infections get the most effective care.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11124043 on NIH RePORTER |
What this research studies
This research investigates the mechanisms by which methicillin-resistant Staphylococcus aureus (MRSA) develops resistance to antibiotics that target its cell envelope. The team will explore how mutations in a specific regulatory system in MRSA contribute to this resistance, particularly in response to treatments like dalbavancin. By studying these mechanisms, the research aims to identify strategies to enhance the effectiveness of existing antibiotics and prevent the emergence of resistant strains. Patients with MRSA infections may benefit from insights gained through this research, potentially leading to improved treatment options.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients suffering from invasive MRSA infections, particularly those who have shown resistance to standard antibiotic treatments.
Not a fit: Patients with infections caused by non-MRSA bacteria or those who do not have antibiotic-resistant infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for MRSA infections, reducing the risk of treatment failure and improving patient outcomes.
How similar studies have performed: Previous research has shown success in understanding antibiotic resistance mechanisms, but this specific approach to MRSA resistance is novel and aims to fill critical knowledge gaps.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Werth, Brian James — University of Washington
- Study coordinator: Werth, Brian James
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.